Aptus Pharma
221.95
+3.95(+1.81%)
Market Cap₹152.31 Cr
PE Ratio-
Company Performance:
1D+1.81%
1M+40.47%
6M+161.61%
1Y+161.61%
5Y+161.61%
View Company Insightsright
Latest news about Aptus Pharma
Apple faces $38 billion fine risk as CCI defends global turnover-based penalty law in antitrust case 7 days ago
The Competition Commission of India defends its global turnover-based penalty law against Apple's legal challenge, arguing it provides necessary deterrence for multinational companies. Apple faces potential fines up to $38 billion following a CCI investigation into alleged app store dominance misuse. The case involves disputes over retrospective application and information disclosure requirements, with broader implications for antitrust enforcement against global technology companies in India.
More news about Aptus Pharma
11Dec 25
Trump Says Apple CEO Discussed Hiring Difficulties in Recent Conversation
Trump disclosed that Apple's CEO shared concerns about hiring difficulties during a recent conversation. The discussion highlighted ongoing recruitment challenges facing the technology sector. This revelation provides insight into current workforce acquisition difficulties experienced by major technology corporations.
21Nov 25
Aptus Pharma Limited Expands into Urology Therapy Segment
Aptus Pharma Limited announces strategic expansion into the urology therapy segment. The company plans to launch multiple products, including Solifenacin Succinate Tablets for overactive bladder and Tamsulosin Hydrochloride Capsules for benign prostatic hyperplasia, subject to regulatory approvals. This move targets the growing global urology devices market, projected to reach $62.76 billion by 2028. The company aims to leverage its existing distribution network and manufacturing capabilities, while exploring partnerships to support growth in this new segment.
11Nov 25
Aptus Pharma Limited Reports Robust 47% Revenue Growth in H1
Aptus Pharma Limited announced robust financial results for H1 FY24. Total revenue increased by 47.38% to Rs. 1,437.75 lakhs, EBITDA grew by 36.12% to Rs. 294.55 lakhs, and PAT rose by 33.81% to Rs. 174.69 lakhs compared to the previous year. The company experienced slight margin compression with EBITDA margin at 20.49% and PAT margin at 12.15%. Growth was attributed to product portfolio expansion, strengthened marketing network, and improved operational efficiency. The company plans to continue investing in new products, digital initiatives, and distribution expansion.
Aptus Pharma
221.95
+3.95
(+1.81%)
1 Year Returns:+161.61%
Industry Peers
LG Electronics
1,388.60
(-0.22%)
Voltas
1,411.40
(-1.98%)
Blue Star
1,806.10
(-0.33%)
Amber Enterprises
6,145.00
(+0.52%)
Crompton Greaves
251.20
(-1.37%)
V-Guard Industries
305.60
(+0.91%)
Eureka Forbes
560.30
(-1.14%)
Whirlpool
801.95
(-0.08%)
TTK Prestige
597.00
(+0.84%)
Symphony
894.50
(-1.07%)